Editas Medicine Announces Second Quarter 2017 Results and Update
Aug 09, 2017 20:03 pm UTC| Business
Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials Achieved research milestone in Juno Therapeutics, Inc., collaboration CAMBRIDGE, Mass., Aug. 09,...
GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
Aug 09, 2017 20:02 pm UTC| Business
Forced vital capacity (FVC) in lungs stabilized over the 12-week treatment period, placebo arm showed expected decline Functional respiratory imaging (FRI) confirms FVC data with statistical significance GLPG1690 was...
Pegasystems Announces Second Quarter 2017 Financial Results
Aug 09, 2017 20:02 pm UTC| Business
License and Cloud Backlog increases 32% year over yearFirst half revenue growth of 15% coupled with operating margin expansion Record operating cash flow of $86 million in first half of 2017 CAMBRIDGE, Mass., Aug. 09,...
FutureFuel Releases Second Quarter and Six-Month 2017 Results
Aug 09, 2017 20:02 pm UTC| Business
FutureFuel Second Quarter Net Income of $0.8 Million Reports Net Income of $0.8 Million or $0.02 per Diluted Share, and Adjusted EBITDA of $2.1 Million CLAYTON, Mo., Aug. 09, 2017 -- FutureFuel Corp. (NYSE:FF)...
Tractor Supply Company Announces Groundbreaking of Northeast Distribution Center
Aug 09, 2017 20:01 pm UTC| Business
BRENTWOOD, Tenn., Aug. 09, 2017 -- Tractor Supply Company (NASDAQ:TSCO), the largest rural lifestyle retail store chain in the United States, announced today it has officially begun construction of a new distribution...
Retrophin Reports Second Quarter 2017 Financial Results
Aug 09, 2017 20:01 pm UTC| Business
Fosmetpantotenate (RE-024) Phase 3 trial underway in PKAN Protocol design for pivotal Phase 3 trial of sparsentan in FSGS complete; sparsentan IP estate expanded to 2030 for FSGS Second quarter revenues increased 16...
Aclaris Announces Proposed Public Offering of Common Stock
Aug 09, 2017 20:01 pm UTC| Business
MALVERN, Pa., Aug. 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, up to $75,000,000...
FxWirePro- Major Economic events to watch